Skip to main content
NVDA+0.55%AAPL-0.95%GOOGL-1.49%MSFT-1.06%AMZN-1.96%TSM-1.03%SPCX-1.98%META+0.02%AVGO-1.03%TSLA-0.38%SKHY+0.60%BRK-B+0.15%LLY+0.39%MU+0.78%JPM-0.97%WMT-0.13%AMD+2.29%V-0.54%XOM+1.61%JNJ-1.09%ASMLa-1.36%0700.HK+1.90%MA-0.80%INTC+1.14%ABBV-0.15%1398.HK-2.09%CSCO+0.45%CVX+1.39%BAC+0.08%ORCL-1.05%COST-1.12%KO-0.70%DELL+4.11%CAT-0.85%HSBA.L-1.56%0005.HK-3.21%PG+0.25%UNH-1.43%LRCX-2.43%AP2d-2.35%AMAT-1.34%1816.HK-0.46%3988.HK-2.13%NFLX-2.82%GE-2.42%MS-2.13%0857.HK+0.60%HD-1.46%PM-0.09%0939.HK-2.83%USDJPY+0.97%NZDUSD-0.92%USDTHB+0.74%CHFJPY+0.73%GBPJPY+0.68%CADJPY+0.68%GBPNZD+0.66%NZDCAD-0.62%NZDCHF-0.59%AUDUSD-0.58%EURUSD-0.48%EURJPY+0.46%EURNZD+0.44%GBPTRY+0.41%AUDJPY+0.41%NOKJPY+0.39%PLNJPY+0.37%AUDNZD+0.34%USDCHF+0.33%GBPHKD+0.32%GBPAUD+0.30%USDCAD+0.30%GBPMXN-0.28%NZDMXN-0.28%AUDCAD-0.26%GBPUSD-0.26%SGDJPY+0.26%USDTRY+0.25%AUDCHF-0.23%EURCAD-0.21%USDSGD+0.20%EURGBP-0.20%USDSEK+0.20%USDILS+0.16%EURSGD+0.15%CHFNOK-0.15%EURSEK+0.14%EURCHF-0.13%EURCZK+0.13%GBPSGD+0.12%NZDSGD-0.12%EURAUD+0.11%AUDDKK-0.09%USDPLN+0.09%USDNOK+0.08%USDCNH+0.08%AUDNOK-0.07%AUDSGD+0.06%USDZAR+0.06%NZDJPY+0.06%USDDKK+0.05%GBPCHF+0.05%EURHKD-0.05%USDMXN+0.04%USDCOP-0.04%EURPLN+0.04%GBPCAD+0.04%CHFSEK-0.03%CHFSGD-0.02%CADCHF+0.02%GBPZAR-0.02%USDHKD+0.02%EURNOK+0.02%EURDKK-0.01%EURZAR+0.01%EURCNH0.00%USOIL+2.67%UKOIL+1.94%W1+1.65%XNGUSD+1.39%COFFEE-0.97%C1+0.80%S1+0.79%SUGAR-0.72%COCOA-0.55%XAUUSD-0.51%GAUUSD-0.51%HG1+0.27%BTCUSD-2.84%ETHUSD-4.23%USDTUSD-0.04%XRPUSD-2.79%SOLUSD-3.58%TRXUSDT-0.41%ZECUSDT-4.17%DOGEUSD-2.84%XMRUSDT-0.09%LINKUSD-2.96%XLMUSD-0.71%BCHUSDT-2.19%UNIUSD-3.98%LTCUSD-2.96%HBARUSDT-0.71%TONUSD+26.79%SUIUSD-3.38%TAOUSDT-3.99%AAVEUSD-3.05%DOTUSDT-2.91%ICPUSDT-7.47%ONDOUSDT-4.25%WLDUSDT-2.35%ARBUSDT+2.72%ATOMUSDT-2.10%JUPUSDT-5.14%INJUSDT-9.70%STXUSDT-3.87%FETUSDT-4.78%PYTHUSDT-5.16%TIAUSDT-6.71%SEIUSDT-3.59%IMXUSDT-1.81%OPUSDT-3.66%GRTUSDT-4.37%WIFUSDT-5.33%POLUSDT-0.50%IOTAUSDT-6.20%AXSUSDT-3.68%FARTCOINUSDT-2.43%EOSUSDT-4.69%DYDXUSDT-6.82%ORDIUSDT-2.55%GALAUSDT-2.06%NOTUSDT-2.37%RONINUSDT-7.55%NVDA+0.55%AAPL-0.95%GOOGL-1.49%MSFT-1.06%AMZN-1.96%TSM-1.03%SPCX-1.98%META+0.02%AVGO-1.03%TSLA-0.38%SKHY+0.60%BRK-B+0.15%LLY+0.39%MU+0.78%JPM-0.97%WMT-0.13%AMD+2.29%V-0.54%XOM+1.61%JNJ-1.09%ASMLa-1.36%0700.HK+1.90%MA-0.80%INTC+1.14%ABBV-0.15%1398.HK-2.09%CSCO+0.45%CVX+1.39%BAC+0.08%ORCL-1.05%COST-1.12%KO-0.70%DELL+4.11%CAT-0.85%HSBA.L-1.56%0005.HK-3.21%PG+0.25%UNH-1.43%LRCX-2.43%AP2d-2.35%AMAT-1.34%1816.HK-0.46%3988.HK-2.13%NFLX-2.82%GE-2.42%MS-2.13%0857.HK+0.60%HD-1.46%PM-0.09%0939.HK-2.83%USDJPY+0.97%NZDUSD-0.92%USDTHB+0.74%CHFJPY+0.73%GBPJPY+0.68%CADJPY+0.68%GBPNZD+0.66%NZDCAD-0.62%NZDCHF-0.59%AUDUSD-0.58%EURUSD-0.48%EURJPY+0.46%EURNZD+0.44%GBPTRY+0.41%AUDJPY+0.41%NOKJPY+0.39%PLNJPY+0.37%AUDNZD+0.34%USDCHF+0.33%GBPHKD+0.32%GBPAUD+0.30%USDCAD+0.30%GBPMXN-0.28%NZDMXN-0.28%AUDCAD-0.26%GBPUSD-0.26%SGDJPY+0.26%USDTRY+0.25%AUDCHF-0.23%EURCAD-0.21%USDSGD+0.20%EURGBP-0.20%USDSEK+0.20%USDILS+0.16%EURSGD+0.15%CHFNOK-0.15%EURSEK+0.14%EURCHF-0.13%EURCZK+0.13%GBPSGD+0.12%NZDSGD-0.12%EURAUD+0.11%AUDDKK-0.09%USDPLN+0.09%USDNOK+0.08%USDCNH+0.08%AUDNOK-0.07%AUDSGD+0.06%USDZAR+0.06%NZDJPY+0.06%USDDKK+0.05%GBPCHF+0.05%EURHKD-0.05%USDMXN+0.04%USDCOP-0.04%EURPLN+0.04%GBPCAD+0.04%CHFSEK-0.03%CHFSGD-0.02%CADCHF+0.02%GBPZAR-0.02%USDHKD+0.02%EURNOK+0.02%EURDKK-0.01%EURZAR+0.01%EURCNH0.00%USOIL+2.67%UKOIL+1.94%W1+1.65%XNGUSD+1.39%COFFEE-0.97%C1+0.80%S1+0.79%SUGAR-0.72%COCOA-0.55%XAUUSD-0.51%GAUUSD-0.51%HG1+0.27%BTCUSD-2.84%ETHUSD-4.23%USDTUSD-0.04%XRPUSD-2.79%SOLUSD-3.58%TRXUSDT-0.41%ZECUSDT-4.17%DOGEUSD-2.84%XMRUSDT-0.09%LINKUSD-2.96%XLMUSD-0.71%BCHUSDT-2.19%UNIUSD-3.98%LTCUSD-2.96%HBARUSDT-0.71%TONUSD+26.79%SUIUSD-3.38%TAOUSDT-3.99%AAVEUSD-3.05%DOTUSDT-2.91%ICPUSDT-7.47%ONDOUSDT-4.25%WLDUSDT-2.35%ARBUSDT+2.72%ATOMUSDT-2.10%JUPUSDT-5.14%INJUSDT-9.70%STXUSDT-3.87%FETUSDT-4.78%PYTHUSDT-5.16%TIAUSDT-6.71%SEIUSDT-3.59%IMXUSDT-1.81%OPUSDT-3.66%GRTUSDT-4.37%WIFUSDT-5.33%POLUSDT-0.50%IOTAUSDT-6.20%AXSUSDT-3.68%FARTCOINUSDT-2.43%EOSUSDT-4.69%DYDXUSDT-6.82%ORDIUSDT-2.55%GALAUSDT-2.06%NOTUSDT-2.37%RONINUSDT-7.55%
JB

Jade Biosciences, Inc. (JBIO)

NASDAQ • Healthcare

$18.18
+$0.28 (+1.6%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$18.06
Previous Close$18.18
Day Range$17.88 - $18.83
Avg. Volume (3M)771.4K
Market Cap$1.1B
52 Week Range
$6.91$28
Next EarningsIn 58 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$153.2M
EPS (TTM)
-$2.75
ROA (TTM)
-32.46%
Current Ratio
14.93
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

0.0%Q1 2026-$0.45
-9.6%Q2 2026-$0.57
-19.4%Q3 2026-$0.76
Next

Nov 12

in 58 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -19.4%

Jade Biosciences’ earnings missed expectations, with EPS of -$0.76 trailing the -$0.64 estimate by -$0.12, based on preliminary results for the second fiscal quarter of 2026 that were reported August 10, 2026. The biotechnology company generated a GAAP operating loss of about $58.9 million, and net income was a loss of roughly $55.8 million, down 73.5% from a loss of about $32.1 million a year ago. Cash burn remained evident, with negative operating cash flow of around $43.7 million during the quarter as the company continues advancing its kidney-disease pipeline, including lead program JADE-001 for IgA nephropathy alongside preclinical programs JADE-002 and JADE-003. Consensus for the next period calls for EPS of -$0.73.

View full earnings history

About Jade Biosciences, Inc.

Jade Biosciences, Inc. is a NASDAQ-listed biotechnology company developing kidney-disease and earlier-stage therapeutic candidates. Trading as JBIO, the company is a small-cap healthcare name whose pipeline centers on JADE-001 for immunoglobulin A, or IgA, nephropathy, alongside two preclinical programs, JADE-002 and JADE-003.

Name
Jade Biosciences, Inc.
CEO
Tom Frohlich
Website
jadebiosciences.com
Industry
Healthcare
Employees
55

Today's Snapshot

AI-generated

The session opened with JBIO slightly lower at 18.16, while its sector was flat.

Trading Volume

Below 10d avg (878.3K)

139.2K

vs S&P 500 Today

Strong Underperformance

-3.68%

Updated: September 15, 2026 at 15:03 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
JBIO leans toward a sell stance around 17.52, as price trades below most short- and medium-term moving averages and the MACD is negative, reflecting downward momentum. Several oscillators show oversold readings—RSI near 31 and stochastic extremely low—so momentum is depressed while some mean-reversion signals are present; however, on-balance volume is weak and volatility is relatively high with an ATR near 1.27, which increases downside sensitivity. The classic pivot sits above price, acting as nearby resistance. Technical takeaway: sell-biased technical profile with elevated volatility and weak volume.
All signals
  • EMA (5 indicators)$17.53 - $20.55
    Sell
  • RSI (14)30.66
    Neutral
  • Stochastic %K (14, 3, 3)7.44
    Buy
  • MACD Level (12, 26)-0.90
    Sell

Peers & Related Assets

TECXTectonic Therapeutic, Inc.
$29.71+2.3%
ALDXAldeyra The
$1.46+9.0%
SLNSilence Therapeutics plc
XOMAXOMA Royalty Corp.
CTNMContineum Therapeutics, Inc.
KYTXKyverna Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.